1. Chen, D.S. and I. Mellman, Oncology meets immunology: thecancer-immunity cycle. Immunity, 2013. 39(1):p. 1-10.
2. Zhang, S. and S.Ren, [Novel Immuno-oncology Therapy:Current Status of Clinical Research and Prospect of Application]. ZhongguoFei Ai Za Zhi, 2017. 20(9): p.645-651.
3. Chen, L. and X.Han, Anti-PD-1/PD-L1 therapy of humancancer: past, present, and future. J Clin Invest, 2015. 125(9): p. 3384-91.
4. Liu, J., et al.,Improved Efficacy of Neoadjuvant Comparedto Adjuvant Immunotherapy to Eradicate Metastatic Disease. CancerDiscovery, 2016. 6(12): p.1382-1399.
5. Liu, L., et al.,Antibody-Targeted TNFRSF Activation forCancer Immunotherapy: The Role of FcγRIIB Cross-Linking. Frontiers in Pharmacology,2022. 13.